Protecting Clients Coast to Coast

Did You Lose Money in WPP plc (NYSE: WPP) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against WPP plc (“WPP” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 8, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. The complaint alleges that WPP and certain executives misled investors about the Company’s expected revenue for fiscal year 2025 and the strength of its media division, GroupM. While expressing confidence in new client wins and claiming to provide “cautious” guidance, WPP allegedly concealed that its media arm was losing market share and struggling to compete amid ongoing macroeconomic challenges. If you purchased WPP securities between February 27, 2025 and July 8, 2025, you may be eligible to recover your losses. Lead Plaintiff Deadline: December 8, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. This caused Plaintiff and other shareholders to purchase aTyr’s securities at artificially inflated prices. In the EFZO-FIT study, efzofitimod failed to show any change in mean daily oral corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma released the results, its stock dropped by 83.25%, from a September 12th market close of $6.03 to a September 15th market close of $1.01. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding ATyr’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the aTyr Pharma class action, go to www.faruqilaw.com/ATYR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Did You Lose Money in Marex Group plc (NASDAQ: MRX) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc (“Marex” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 8, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex’s financial statements could not be relied upon; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased Marex securities between May 16, 2024 and August 5, 2025, you may be eligible to recover your losses. Lead Plaintiff Deadline: December 8, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.  

If you suffered losses in Molina between February 5, 2025 and July 23, 2025, both dates inclusive (the “Class Period”) Securities Litigation Partner James (Josh) Wilson encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) or you can submit your information below. Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. CASE DETAILS: As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. STOCK DROP: On July 7, 2025, before the market opened, Molina issued a press release announcing financial results for the second quarter of 2025 and slashing full year 2025 adjusted earnings per share guidance. The press release revealed the Company’s second quarter 2025 adjusted earnings of approximately $5.50 per share, which was “below its prior expectations” due to “medical cost pressures in all three lines of business.” The Company announced it “expects these medical cost pressures to continue into the second half of the year” and cut guidance for expected adjusted earnings per share 10.2% at the midpoint, from “at least $24.50 per share” to a “range of $21.50 to $22.50 per share.” The press release revealed Molina was experiencing a “short-term earnings pressure” from a “dislocation between premium rates and medical cost trend which has recently accelerated.” On this news, Molina’s stock price fell $6.97, or 2.9%, to close at $232.61 per share on July 7, 2025, on unusually heavy trading volume. Then, on July 23, 2025, after the market closed, Molina issued a press release reporting its financial results for the second quarter ended June 30, 2025 and further slashing the Company’s full-year 2025 earnings guidance. The press release revealed, in part, that the Company’s “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year;” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share.” This represented another 13.6% cut to guidance of earnings per share at the midpoint, from the cut to guidance announced less than two weeks earlier. The Company also cut its guidance for its full year 2025 GAAP net income 27% to $912 million. The Company attributed its results a full year outlook to a “challenging medical cost trend environment,” including mere “utilization of behavioral health, pharmacy, and inpatient and outpatient services.” The Company alleged its guidance cut also reflected “new information gained in the quarterly closing process.” On this news, Molina’s stock price fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume. WHAT’S NEXT? If you incurred a loss in Molina Therapeutics during the class period, you have until the December 2, 2025 deadline, to petition the Court for appointment as lead plaintiff. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Molina’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.